Cell and gene therapy manufacturing India took a step forward on 21 October 2026, when Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, and Hyderabad-based VeGen Bio announced a partnership for VL-2511, an experimental dual-target BCMA/CD19 CAR-T therapy for multiple myeloma. Nucelion will provide technology transfer, process development and manufacturing, and the companies plan Phase 1/2 trials in India with 2028 as a commercialisation target, subject to approvals. The deal is a manufacturing arrangement, not a marketing one. This industry report looks at the contract development and manufacturing model, what the deal leaves out and what would make it succeed. It is not investment advice.
Cell and gene therapy manufacturing India: key takeaways
- Nucelion is described as one of India’s first dedicated cell and gene therapy contract research, development and manufacturing organisations.
- The scope covers technology transfer, process development and clinical- and commercial-stage manufacturing; marketing and distribution are excluded.
- VeGen Bio brings the therapy; the framework is meant to host other VeGen Bio candidates later.
- The partners aim to raise yields and efficiency to lower production cost, but no cost or price figures were given.
- No financial terms, trial dates or patient numbers were disclosed.
The deal in outline for cell and gene therapy manufacturing India
According to published reports, Nucelion will help move VL-2511 from the developer’s process to a reproducible manufacturing process, produce material for trials and eventually support commercial supply. One report says the single-site facility is designed to meet CDSCO, US FDA and EMA standards and that Nucelion will use its facility in Hyderabad; the other report does not give a location. Nucelion’s website, Nucelion, describes its services. We have not seen the agreement and no financial terms were reported.
How a CRDMO works in cell and gene therapy manufacturing India
General background: a CRDMO offers developers a ready facility, trained staff and quality systems so they do not have to build their own. For an autologous cell therapy, the work includes receiving a patient’s cells, modifying and expanding them, testing them and returning them on a tight schedule, with the whole chain documented for regulators. The model suits small developers with a promising product but no plant. It also puts a premium on reliability, since a failed batch is a failed treatment for a patient.
What Nucelion says about the manufacturing challenge
Nucelion’s chief business officer Raghu Malapaka was quoted as saying that many CAR-T programmes stall between a promising construct and a product that can be made reliably at scale. VeGen Bio’s director Prashant Bhavar said CAR-T cell therapy holds significant promise for patients with serious cancers. These are company statements. The point about scale-up is borne out generally in the field, where process development often decides how quickly a programme reaches patients.
What a developer looks for in a manufacturing partner
This section is our analysis. A developer choosing a manufacturing partner for a cell therapy would typically weigh the partner’s record with similar processes, the quality systems that regulators will inspect, the ability to scale from trial batches to commercial supply, the cost per batch and the security of the supply chain for vectors and other inputs. Nucelion’s reported ambition to meet CDSCO, US FDA and EMA standards speaks to the second point, but standards on paper are not the same as inspected performance, and no inspection history was reported.
Cost, yield and access in cell and gene therapy manufacturing India
This section is our analysis. Cell therapy cost depends on factors such as how many patients a facility can process, the share of batches that meet specifications and the cost of raw materials and testing. Improving yield and efficiency, which the partners say they will do, can lower cost per dose, but the reports give no figures, so no saving can be assumed. Lower cost matters to access only if the therapy proves safe and effective in trials and receives approval.
The wider Nucelion pipeline in cell and gene therapy manufacturing India
One report lists Nucelion’s earlier partnerships: Pandorum Technologies of Bengaluru in January 2026 on regenerative therapies for eye diseases, the Nordic Cell Therapy Group of Denmark on cell therapy development, and Quantoom Biosciences of Belgium on RNA manufacturing in India. We have not verified those details independently. They suggest the company is building a service base across several modalities, which could spread risk if any one programme fails, though the reports give no revenue or capacity figures.
India’s CAR-T context
The same report says India’s indigenous CAR-T treatment, NexCAR19, was developed with IIT Bombay, Tata Memorial Centre and ImmunoACT. A second domestic programme would add to the field. VL-2511 is at an earlier stage: the companies plan Phase 1/2 trials, which would be registered with the Clinical Trials Registry of India, and any approval would come from the Central Drugs Standard Control Organisation after review of trial data. As we understand Indian rules, cell-based products are regulated as new drugs, so developers should confirm current requirements.
What is not disclosed about cell and gene therapy manufacturing India
- Financial terms, capacity, and the investment behind the facility.
- Trial design, sites, patient numbers and start date.
- Clinical results for VL-2511 from earlier studies.
- Expected pricing and the target patient population.
Risks and caveats on cell and gene therapy manufacturing India
- VL-2511 is experimental, and manufacturing capacity does not ensure clinical success.
- The 2028 target depends on clinical progress and approvals.
- Company statements have not been independently verified.
- This is news reporting, not investment advice.
In our assessment, the deal strengthens the case that cell and gene therapy manufacturing India can be built around contract partners, but its value will be judged by trial data and by whether Nucelion can deliver consistent batches at scale. More in our industry insights coverage.
What to watch next on cell and gene therapy manufacturing India
- Registration and start of the Phase 1/2 trial.
- Additional VeGen Bio programmes under the framework.
- Further Nucelion partnerships and disclosures of capacity.
Frequently asked questions
What is Nucelion?
A Bharat Biotech subsidiary described as a cell and gene therapy contract research, development and manufacturing organisation.
Does the deal cover marketing?
No. The reports describe a manufacturing and development arrangement, not marketing or distribution.
When could VL-2511 be commercial?
The companies name 2028 as a target, subject to clinical progress and regulatory approvals.
How we reported this: we relied on published reports of the 21 October 2026 announcement and the company website, and we did not see the agreement. General background and our analysis are labelled. Last updated: 23 October 2026. This article is news reporting and not investment advice.
